NO875232L - Stabile preparater av ricin-toksin-a-kjede og av rta-immunokonjugater og stabilisator-utsorteringsmetoder derav. - Google Patents

Stabile preparater av ricin-toksin-a-kjede og av rta-immunokonjugater og stabilisator-utsorteringsmetoder derav.

Info

Publication number
NO875232L
NO875232L NO875232A NO875232A NO875232L NO 875232 L NO875232 L NO 875232L NO 875232 A NO875232 A NO 875232A NO 875232 A NO875232 A NO 875232A NO 875232 L NO875232 L NO 875232L
Authority
NO
Norway
Prior art keywords
immunoconjugates
rta
ricin
toxin
stabilizer
Prior art date
Application number
NO875232A
Other languages
English (en)
Other versions
NO875232D0 (no
Inventor
Robert Ferris
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Publication of NO875232D0 publication Critical patent/NO875232D0/no
Publication of NO875232L publication Critical patent/NO875232L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/02—Food
    • G01N33/14—Beverages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A61K47/6827—Ricin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/861—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgG3, IgG4, IgA, or IgY

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
NO875232A 1986-12-19 1987-12-15 Stabile preparater av ricin-toksin-a-kjede og av rta-immunokonjugater og stabilisator-utsorteringsmetoder derav. NO875232L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/944,347 US4808705A (en) 1986-12-19 1986-12-19 Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor

Publications (2)

Publication Number Publication Date
NO875232D0 NO875232D0 (no) 1987-12-15
NO875232L true NO875232L (no) 1988-06-20

Family

ID=25481236

Family Applications (1)

Application Number Title Priority Date Filing Date
NO875232A NO875232L (no) 1986-12-19 1987-12-15 Stabile preparater av ricin-toksin-a-kjede og av rta-immunokonjugater og stabilisator-utsorteringsmetoder derav.

Country Status (11)

Country Link
US (1) US4808705A (no)
EP (1) EP0271918A3 (no)
JP (1) JPS63258426A (no)
AU (1) AU593489B2 (no)
CA (1) CA1305417C (no)
DK (1) DK670587A (no)
FI (1) FI875608A7 (no)
HU (1) HUT45401A (no)
IE (1) IE873452L (no)
IL (1) IL84876A0 (no)
NO (1) NO875232L (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5393512A (en) * 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
US5116944A (en) * 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5270057A (en) * 1990-03-20 1993-12-14 Akzo N.V. Stabilized gonadotropin containing preparations
KR100361933B1 (ko) * 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
ATE406577T1 (de) * 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
US6458953B1 (en) * 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
US20070020662A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computerized control of high-throughput experimental processing and digital analysis of comparative samples for a compound of interest
US20070021929A1 (en) * 2000-01-07 2007-01-25 Transform Pharmaceuticals, Inc. Computing methods for control of high-throughput experimental processing, digital analysis, and re-arraying comparative samples in computer-designed arrays
CA2414076A1 (en) * 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
PT1343518E (pt) * 2000-11-07 2009-08-03 Novartis Vaccines & Diagnostic Composições de interferão estabilizadas
ATE454137T1 (de) 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
US20100210027A9 (en) * 2002-11-04 2010-08-19 Hongming Chen Method for determining effect of preformulation forms on their dissolution rates
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
FR2877565A1 (fr) * 2004-11-09 2006-05-12 Oreal Utilisation d'un sulfate de dextran de haut poids moleculaire comme agent apaisant
CA2615731A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
EP1980853A1 (en) * 2007-04-11 2008-10-15 Alfresa Pharma Corporation Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle
US20080261328A1 (en) * 2007-04-19 2008-10-23 Alfresa Pharma Corporation Method of preventing precipitation of a reactive substance-bound microparticle, and reagent containing the micro particle
CN106822891A (zh) 2008-06-20 2017-06-13 诺华公司 具有降低的聚集的免疫球蛋白
WO2011121560A2 (en) 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
JP2013523717A (ja) 2010-03-31 2013-06-17 ユニベルシテ ドゥ ジュネーブ 安定化された抗体調製物およびその使用
GB201717966D0 (en) * 2017-10-31 2017-12-13 Xenikos Bv Immunotoxins, formulations thereof and their use in medicine
CN111781345A (zh) * 2020-06-30 2020-10-16 上海透景生命科技股份有限公司 化学发光标记物标记抗原稳定剂及其应用
CN119498456A (zh) * 2024-12-10 2025-02-25 山东海创工贸有限公司 一种利用奶制品和肉产品作为原料的宠物湿粮及其制作方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
US4439181A (en) * 1981-01-26 1984-03-27 Regents Of The University Of Minnesota Polyol-hormone mixture for use in chronic parenteral hormone administration
JPS59116229A (ja) * 1982-12-24 1984-07-05 Teijin Ltd 細胞毒性複合体を活性成分とする癌治療用剤およびその製造法
US4664911A (en) * 1983-06-21 1987-05-12 Board Of Regents, University Of Texas System Immunotoxin conjugates employing toxin B chain moieties
ATE87318T1 (de) * 1985-11-29 1993-04-15 Consolidated Pharmaceuticals L Ricin-antikoerper-konjugate.

Also Published As

Publication number Publication date
DK670587A (da) 1988-06-20
HUT45401A (en) 1988-07-28
FI875608A0 (fi) 1987-12-18
IE873452L (en) 1988-06-19
US4808705A (en) 1989-02-28
AU593489B2 (en) 1990-02-08
AU8280187A (en) 1988-06-23
FI875608A7 (fi) 1988-06-20
JPS63258426A (ja) 1988-10-25
NO875232D0 (no) 1987-12-15
CA1305417C (en) 1992-07-21
EP0271918A3 (en) 1989-12-13
EP0271918A2 (en) 1988-06-22
IL84876A0 (en) 1988-06-30
DK670587D0 (da) 1987-12-18

Similar Documents

Publication Publication Date Title
NO875232D0 (no) Stabile preparater av ricin-toksin-a-kjede og av rta-immunokonjugater og stabilisator-utsorteringsmetoder derav.
NO872585D0 (no) Fremstilling og anvendelse av stabiliseringsmiddel for leire.
IT1205010B (it) Tetraidronaftalin-derivati e indan-derivati
DK330087A (da) Solfilter-forbindelse og sammensaetning indeholdende samme
NO861234L (no) Fremgangsmaate for ekstraksjon og opprensing av proteiner.
DK10289D0 (da) Fremgangsmaade og praeparater til forebyggelse af ulcus
DK149988D0 (da) Stabile farmaceutiske praeparater
NO882390L (no) (ih-azol-1-ylmetyl)substituerte benzotriazolderivater og deres fremstilling.
DK412787A (da) Medicinsk-kirurgisk pose og dennes fremstilling
NO165494C (no) Aminosalter av lignosulfonater og anvendelse derav.
DK127887A (da) Interleukin-1beta-derivater og medikamenter indeholdende saadanne derivater
NO873454L (no) Fremstilling og anvendelse av faste fytoaktive blandinger.
NO884566L (no) Anvendelse av fluorderivater og kontrastpreparat for diagnostisering av ondartede neoplasmer.
NO882462L (no) Fremstilling og bruk av fenolderivater.
DK413187A (da) Semicarbazoner og thiosemicarbazoner
NO872140D0 (no) Polyetere, fremstilling og anvendelse av slike.
NO890061D0 (no) Fremstilling og anvendelse av gallosilikataromatiseringskatalysator.
DK397788D0 (da) Polyarylalkan-oligomer-praeparater og fremgangsmaade til fremstilling deraf
DK226487D0 (da) Emulgeringsmiddel og emulsion indeholdende dette
NO873197D0 (no) Bedoevelsespreparat og fremgangsmaate for anvendelse av dette.
NO881713L (no) Fremgangsmaate for fremstilling av di-t-butylfenyl-alkyl og benzylethere.
DK434388D0 (da) Fremgangsmaade og anlaeg til informationssoegning
TR23973A (tr) Feniltio uereler fenilnoti uereler ve fenil karbodi- imidler bunlarin elde edilmeleri
DK127187D0 (da) Farmaceutisk kombination af t-pa og oxypurinol
NO901421D0 (no) Intranasal administrering av fysostigmin og arecolin.